Monoclonal antibodies targeting the PD-L1 / PD-1 immune checkpoint are currently revolutionizing systemic cancer treatment [32, 33] but their efficacy for intracranial tumors is less certain given their poor blood-brain barrier penetration. The gene discussed is CD274; the disease is cancer.